Kiniksa Pharmaceuticals International (KNSA) total liabilities
Kiniksa Pharmaceuticals International (KNSA) had total liabilities of $196.03M at the end of fiscal 2025 (December 31, 2025). That is 37.9% higher than the $142.12M of fiscal 2024. Figures as of 19 Nov 2026, 11:36 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Total liabilities, fiscal 2025
- $196.03M
- Change on fiscal 2024
- +37.9%
- Growth, 5 years
- +39.2% a year
- Highest on record
- $196.03Mfiscal 2025
- Lowest on record
- $17.43Mfiscal 2017
- Fiscal years on record
- 92017–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Kiniksa Pharmaceuticals International total liabilities, in more detail
Over the five fiscal years to 2025 total liabilities grew at a compound 39.2% a year. Across the 9 fiscal years on record (2017–2025), the highest was $196.03M in fiscal 2025 and the lowest $17.43M in fiscal 2017.
Total liabilities by fiscal year
Kiniksa Pharmaceuticals International total liabilities, year by year
| Fiscal year | Total liabilities | Change | Year ended |
|---|---|---|---|
| 2025 | $196.03M | 37.9% up | |
| 2024 | $142.12M | 62.5% up | |
| 2023 | $87.48M | 37.7% up | |
| 2022 | $63.52M | 33.0% up | |
| 2021 | $47.76M | 27.3% up | |
| 2020 | $37.53M | 28.9% up | |
| 2019 | $29.11M | 31.8% down | |
| 2018 | $42.70M | 145.0% up | |
| 2017 | $17.43M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.
How to read it
It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.
Total liabilities at health care companies of similar size
| Company | Total liabilities | Fiscal year |
|---|---|---|
| Alkermes ALKS | $667.70M | 2025 |
| PACS Group PACS | $4.63B | 2025 |
| Kiniksa Pharmaceuticals International KNSA | $196.03M | 2025 |
| ImmunityBio IBRX | $1.00B | 2025 |
| Cytokinetics CYTK | $2.08B | 2025 |
| ABIVAX ABVX | €129.14M | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Kiniksa Pharmaceuticals International, figure by figure
- Kiniksa Pharmaceuticals International market cap
- Kiniksa Pharmaceuticals International revenue
- Kiniksa Pharmaceuticals International earnings
- Kiniksa Pharmaceuticals International earnings per share (EPS)
- Kiniksa Pharmaceuticals International P/E ratio
- Kiniksa Pharmaceuticals International P/S ratio
- Kiniksa Pharmaceuticals International P/B ratio
- Kiniksa Pharmaceuticals International free cash flow
- Kiniksa Pharmaceuticals International operating margin
- Kiniksa Pharmaceuticals International dividend
- Kiniksa Pharmaceuticals International shares outstanding
- Kiniksa Pharmaceuticals International total debt
- Kiniksa Pharmaceuticals International cash on hand
- Kiniksa Pharmaceuticals International total assets
- Kiniksa Pharmaceuticals International net assets (shareholders' equity)
- Kiniksa Pharmaceuticals International return on equity (ROE)
- Kiniksa Pharmaceuticals International return on invested capital (ROIC)
Kiniksa Pharmaceuticals International (KNSA) overview: price, valuation and scorecardAll health care companies by market value
Kiniksa Pharmaceuticals International total liabilities: questions and answers
How large are Kiniksa Pharmaceuticals International's total liabilities?
Kiniksa Pharmaceuticals International (KNSA) had total liabilities of $196.03M at the end of fiscal 2025 (December 31, 2025). That is 37.9% higher than the $142.12M of fiscal 2024.
What is the growth rate of Kiniksa Pharmaceuticals International's total liabilities?
Over the five fiscal years to 2025 total liabilities grew at a compound 39.2% a year.
What are the highest and lowest total liabilities figures on record for Kiniksa Pharmaceuticals International?
Across the 9 fiscal years on record (2017–2025), the highest was $196.03M in fiscal 2025 and the lowest $17.43M in fiscal 2017.
How is Kiniksa Pharmaceuticals International's total liabilities calculated?
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Kiniksa Pharmaceuticals International it is on record here for 9 fiscal years, 2017 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: total liabilities
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Kiniksa Pharmaceuticals International (KNSA) total liabilities”, data as of 19 November 2026. https://funkfolio.com/stock/KNSA/total-liabilities
Underlying data: the company's filings with the SEC and Yahoo Finance.